Skip to main content
SpringerLink
Log in

Potential Effects of Antibody Induction by Protein Drugs

  • Chapter
Protein Pharmacokinetics and Metabolism

Part of the book series: Pharmaceutical Biotechnology ((PBIO,volume 1))

Abstract

The immunogenicity of proteins has long been exploited medically, both to inactivate plant and animal toxins after accidental exposure (by passive immunization with antibodies that function as antitoxins to neutralize the biological effects of the toxin) and to provide protection from diseases (by vaccination with living attenuated or killed infectious agents to stimulate adaptive resistance). More recently, considerable research has been devoted to using synthetic or recombinant peptides and proteins, which do not pose the disease risk of attenuated living agents, in an attempt to stimulate the production of neutralizing antibody to a variety of disease vectors (Mackett and Arrand, 1985; Wroblewska et al., 1985; Chanh et al., 1986; Putney et al., 1986; Francis et al., 1987; Krohn et al., 1987; Tomley et al., 1987; Britta et al., 1988; Goudsmit et al., 1988; Michel et al., 1988).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • Britt, W. J., Vugler, L., and Stephens, E. B., 1988, Induction of complement-dependent and-independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-l 16 (gB), J. Virol 62:3309–3318.

    PubMed  CAS  Google Scholar 

  • Capon, D. J., Chamow, S. M., Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, H., Byrn, R. A., Lucas, C., Wurm, F. M., Groopman, J. E., Broder, S., and Smith, D. H., 1989, Designing CD4 immunadhesins for AIDS therapy, Nature 337:525–531.

    Article  PubMed  CAS  Google Scholar 

  • Chanh, T. C., Dreesman, G. R., Kanda, P., Linette, G. P., Sparrow, J. R., Ho, D. D., and Kennedy, R. C., 1986, Induction of anti-HIV neutralizing antibodies by synthetic peptides, EMBO J. 5:3065–3071.

    PubMed  CAS  Google Scholar 

  • Clark, J. W., and Longo, D. L., 1987, Interferons in cancer therapy, Cancer Princ. Pract. Oncol. Update 4:1–16.

    Google Scholar 

  • Figlin, R. A., and Itri, L. M., 1988, Anti-interferon antibodies: A perspective, Semin. Hematol. 25(Suppl. 3):9–15.

    PubMed  CAS  Google Scholar 

  • Figlin, R. A., deKernion, J. B., Mukamel, E., Palleroni, A. V., Itri, L. M., and Sarna, G. P., 1988, Recombinant interferon alfa-2a in metastatic renal cell carcinoma: Assessment of antitumor activity and anti-interferon antibody formation, J. Clin. Oncol 6:1604–1610.

    PubMed  CAS  Google Scholar 

  • Fineberg, S., Galloway, J., Fineberg, N., Rathbun, M., and Hufferd, S., 1983, Immunogenicity of recombinant DNA human insulin, Diabetologia 25:465–469.

    Article  PubMed  CAS  Google Scholar 

  • Francis, M. J., Hastings, G. Z., Sangar, D. V., Clark, R. P., Syred, A., Clarke, B. E., Rowlands, D. J., and Brown, F., 1987, A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2, J. Gen. Virol. 68:2687–2691.

    Article  PubMed  CAS  Google Scholar 

  • Freund, M., Von Wussow, P., Diedrich, H., Eisert, R., Link, H., Wilke, H., Buchholz, F., LeBlanc, S., Fonatsch, C., Deicher, H., and Poliwoda, H., 1989, Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies, Br. J. Haematol. 72:350–356.

    Article  PubMed  CAS  Google Scholar 

  • Golomb, H., Ratain, M., Fefer, A., Thomason, J., Golde, D. W., Ozer, H., Portlock, C., Silber, R., Rappeport, J., and Bonnern, E., 1988, Randomized study of the duration of treatment with interferon alpha-2b in patients with hairy cell leukemia, J. Natl. Cancer Inst. 80:369–373.

    Article  PubMed  CAS  Google Scholar 

  • Golub, E. S., 1987, Immunology: A Synthesis, Sinauer Associates, Sunderland, Mass.

    Google Scholar 

  • Goudsmit, J., Debouck, C., Meloen, R. H., Smit, L., Bakker, M., Asher, D. M., Wolff, A. V., Gibbs, C. J., Jr., and Gajdusek, D. C., 1988, Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees, Proc. Natl. Acad. Sci. USA 85:4478–4482.

    Article  PubMed  CAS  Google Scholar 

  • Groesbeck, M. D., and Parlow, A. F., 1987, Highly improved precision of the hypoph-ysectomized female rat body weight gain bioassay for growth hormone by increased frequency of injections, avoidance of antibody formation, and other simple modifications, Endocrinology 120:2582–2590.

    Article  PubMed  CAS  Google Scholar 

  • Hawkins, M., Horning, S., Konrand, M., Anderson, S., Sielaff, K., Rosno, S., Schiesel, J., Davis, T., DeMets, D., and Merigan, T., 1985, Phase I evaluation of a synthetic mutant of ß-interferon, Cancer Res. 45:5914–5920.

    PubMed  CAS  Google Scholar 

  • Hoitsma, A. J., Reekers, P., Kreeftenberg, J. G., VanLier, H. J. J., Capel, P. J. A., and Koene, R. A. P., 1982, Treatment of acute rejection of cadaveric renal allografts with rabbit antilymphocyte globulin, Transplantation 33:12–16.

    Article  PubMed  CAS  Google Scholar 

  • Itri, L. M., Campion, M., Dennin, R. A., Palleroni, A. V., Gutterman, J. U., Groop-man, J. E., and Trown, P. W., 1987, Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alfa-2a by intramuscular injection, Cancer 59:668–674.

    Article  PubMed  CAS  Google Scholar 

  • Itri, L. M., Sherman, M. I., Palleroni, A. V., Evans, L. M., Tran, L.-L., Campion, M., and Chizzonite, R., 1989, Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha-2. J. Interferon Res. 9(Suppl. 1):S9–S15.

    PubMed  Google Scholar 

  • Jones, G. J., and Itri, L. M., 1986, Safety and tolerance of recombinant interferon-alfa-2A (Roferon-A) in cancer patients, Cancer 57:1709–1715.

    Article  PubMed  CAS  Google Scholar 

  • Kaplan, S. L., August, G. P., Blethen, S. L., Brown, D. R., Hintz, R. L., Johansen, A., Plotnick, L. P., Underwood, L. E., Bell, J. J., Blizzard, R. M., Foley, T. P., Hopwood, N. J., Kirkland, R. T., Rosenfeld, R. G., and Van Wyck, J. J., 1986, Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children, Lancet 1:697–700.

    Article  PubMed  CAS  Google Scholar 

  • Koeller, J. M., 1989, Biologic response modifiers: The interferon alfa experience, Am. J. Hosp. Pharm. 46(Suppl. 2):S11–S15.

    PubMed  CAS  Google Scholar 

  • Konrad, M., Childs, A., Merigan, T., and Bordon, E., 1987, Assessment of the anti-genic response in humans to a recombinant mutant interferon beta, J. Clin. Immunol. 7:365–375.

    Article  PubMed  CAS  Google Scholar 

  • Krigel, R. L., Padavic-Shaller, K. A., Rudolph, A. R., Litwin, S., Konrad, M., Bradley, E. C., and Comis, R. L., 1988, A Phase I study of recombinant interleukin 2 plus recombinant β-interferon, Cancer Res. 48:3875–3881.

    PubMed  CAS  Google Scholar 

  • Krohn, K., Robey, W. G., Putney, S., Arthur, L., Nara, P., Fischinger, P., Gallo, R. C., Wong-Staal, F., and Ranki, A., 1987, Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphocyte virus type IIIB and in human immunodeficiency virus-infected men, Proc. Natl. Acad. Sci. USA 84: 4994–4998.

    Article  PubMed  CAS  Google Scholar 

  • Larocca, A. P., Leung, S. C., Marcus, S. G., Colby, C. B., and Borden, E. C., 1989, Evaluation of neutralizing antibodies in patients treated with recombinant inter-feron-βser, J. Interferon Res. 9(Suppl. 1):S51–S60.

    PubMed  Google Scholar 

  • Larson, S. M., Brown, J. P., Wright, P. W., Carrasquillo, J. A., Hellstrom, I., and Hellstrom, K. E., 1983, Imaging of melanoma with I-131-labeled monoclonal antibodies, J. Nucl. Med. 24:123–129.

    PubMed  CAS  Google Scholar 

  • Laurian, Y., Girma, J. P., Lambert, T., Meyer, D., and Larrieu, M. J., 1984, Incidence of immune responses following 102 infusions of autoplex in 18 hemophilic patients with antibody to factor VIII, Blood 63:457–462.

    PubMed  CAS  Google Scholar 

  • Mackett, M., and Arrand, J. R., 1985, Recombinant vaccinia virus induces neutralising antibodies in rabbits against Epstein-Barr virus membrane antigen gp340, EMBO J. 4:3229–3234.

    PubMed  CAS  Google Scholar 

  • Martin, W. J., II, Blumenthal, M., Roitman, M. S., Condie, R., Simmons, R., and Najarian, J., 1976, Antilymphoblast globulin in renal transplant patients: No allergic reactions, J. Am. Med. Assoc. 236:1729–1735.

    Article  Google Scholar 

  • Michel, M.-L., Mancini, M., Sobczak, E., Favier, V., Guetard, D., Bahraqui, E. M., and Tiollais, P., 1988, Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen proteins, Proc. Natl. Acad. Sci. USA 85:7957–7961.

    Article  PubMed  CAS  Google Scholar 

  • Murasko, D. M., and Blankenhorn, E. P., 1984, Genetic control of neutralizing antibody response to mouse interferon in rats, J. Interferon Res. 4:435–440.

    Article  PubMed  CAS  Google Scholar 

  • Nagabhushan, T. L., Surprenant, H., Le, H. V., Kosecki, R., Levine, A., Reichert, P., Sharma, B., Tsai, H., Trotta, P., Bausch, J., Foster, J., Gruber, S., Hoogerheide, J., and Mecorelli, S., 1984, Characterization of genetically engineered β2 inter-feron, in: Interferons: Research. Clinical Application and Regulatory Consideration (K. C. Zoon, P. D. I. Noguchi, and T.-Y. Liu, eds.), Elsevier, Amsterdam, pp. 79–88.

    Google Scholar 

  • Nilsson, I. M., Berntorp, E., Zettervall, O., and Dahlback, B., 1990, Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients, Blood 75:378–383.

    PubMed  CAS  Google Scholar 

  • Oberg, K., and Alm, G. V., 1989, Development of neutralizing interferon antibodies after treatment with recombinant interferon-α2b in patients with malignant carcinoid tumors, J. Interferon Res. 9(Suppl. 1):S45–S49.

    PubMed  Google Scholar 

  • Oberg, K., Aim, G., Magnusson, A., Lundqvist, G., Theodorsson, E., Wide, L., and Wilander, E., 1989, Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: Development of neutralizing interferon antibodies and possible loss of tumor activity, J. Natl. Cancer Inst. 81:531–535.

    Article  PubMed  CAS  Google Scholar 

  • Pimm, M. V., and Baldwin, R. W., 1990, Syngeneic anti-idiotypic antibody prevents localization of a murine monoclonal antibody in human tumour xenografts, Eur. J. Cancer 26:567–568.

    Article  PubMed  CAS  Google Scholar 

  • Pimm, M. V., Perkins, A. C., Armitage, N. C., and Baldwin, R. W., 1985, The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on the localization of radiolabeled monoclonal antibody in cancer patients, J. Nucl. Med. 26:1011–1023.

    PubMed  CAS  Google Scholar 

  • Putney, S. D., Matthews, T. J., Robey, W. G., Lynn, D. L., Robert-Guroff, M., Mueller, W. T., Langlois, A. J., Ghrayeb, J., Petteway, S. R., Jr., Weinhold, K. J., Fischinger, P. J., Wong-Staal, F., Gallo, R. C., and Bolognesi, D. P., 1986, HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope, Science 234:1392–1395.

    Article  PubMed  CAS  Google Scholar 

  • Quesada, J. R., and Gutterman, J. U., 1983, Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients, J. Natl. Cancer Inst. 70:1041–1046.

    PubMed  CAS  Google Scholar 

  • Quesada, J. R., Rios, A., Swanson, D., Trown, P., and Gutterman, J. U., 1985, Antitumor activity of recombinant-derived interferon alpha in metastatic renal carcinoma, J. Clin. Oncol. 3:1522–1528.

    PubMed  CAS  Google Scholar 

  • Rosenblum, M. G., Unger, B. W., Gutterman, J. U., Hersh, E. M., David, G. S., and Fincke, J. M., 1985, Modification of human leucocyte interferon pharmacology with monoclonal antibody, Cancer Res. 45:2421–2424.

    PubMed  CAS  Google Scholar 

  • Sarna, G., Pertcheck, M., Figlin, R., and Ardalan, B., 1986, Phase I study of recombinant β ser 17 interferon in the treatment of cancer, Cancer Treat. Rep. 70:1365–1372.

    PubMed  CAS  Google Scholar 

  • Satoh, P., Elberg, A., Davis, J., Uittenbogaart, C., Fine, R., and Hardy, M. A., 1979, Effects of different ATG (ATGAM) regimens on the levels of rosette-forming cells (RFC), serum horse IgG (Hol), and anti-horse antibodies in kidney transplant recipients, Transplant. Proc. 11:1427–1439.

    PubMed  CAS  Google Scholar 

  • Sedmark, J. J., and Grossberg, S. E., 1989, High levels of circulating neutralizing antibody in normal animals to recombinant interferon-βser, J. Interferon Res. 9(Suppl. 1):S61–S65.

    Google Scholar 

  • Sell, S., 1987, Immunology, Immunopathology and Immunity, 4th ed., Elsevier, Amsterdam.

    Google Scholar 

  • Sidney, P., Burde, K., and Ortaldo, J., 1984, The human interferons and their biologic activities, in: Interferons: Research. Clinical Application and Regulatory Consideration (K. C. Zoon, P. D. I. Noguchi, and T.-Y. Liu, eds.), Elsevier, Amsterdam, pp. 59–77.

    Google Scholar 

  • Spiegel, R. J., Spicehandler, J. R., Jacobs, S. L. and Oden, E. M., 1986, Low incidence of neutralizing factors in patients receiving recombinant-alfa-2b interferon (Intron-A), Am. J. Med. 80:223–228.

    Article  PubMed  CAS  Google Scholar 

  • Spiegel, R. J., Jacobs, S. L., and Treuhaft, M. W., 1989, Anti-interferon antibodies to interferon-α2b: Results of comparative assays and clinical perspective, J. Interferon Res. 9(Suppl. 1):S17–S24.

    PubMed  Google Scholar 

  • Steis, R. G., Smith, J. W., II, Urba, W. J., Clark, J. W., Itri, L. M., Evans, L. M., Schoenberger, C., and Longo, D. L., 1988, Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies, N. Engl. J. Med. 318:1409–1413.

    Article  PubMed  CAS  Google Scholar 

  • Tomley, F. M., Mockett, A. P. A., Boursnell, M. E. G., Binns, M. M., Cook, J. K. A., Brown, T. D. K., and Smith, G. L., 1987, Expression of the infectious bronchitis virus spike protein by recombinant vaccinia virus and induction of neutralizing antibodies in vaccinated mice, J. Gen. Virol. 68:2291–2298.

    Article  PubMed  CAS  Google Scholar 

  • Trown, P. W., Kramer, M. J., Dennin, R. A., Connel, E. V., Palleroni, A. V., Quesada, J., and Gutterman, J. U., 1983, Antibodies to human leukocyte interferon in cancer patients, Lancet 1:81–84.

    Article  PubMed  CAS  Google Scholar 

  • Vallbracht, A., Treuner, J., Flehmig, B., Joester, K. E., and Niethammer, D., 1981, Interferon neutralizing antibodies in a patient treated with human fibroblast interferon, Nature 289:496–497.

    Article  PubMed  CAS  Google Scholar 

  • Van Kroonenburgh, N. J. P. G., and Pauwels, E. K. J., 1988, Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases, Nucl. Med. Commun. 9:919–930.

    Article  PubMed  Google Scholar 

  • Von Wussow, P., Freund, M., Block, B., Diedrich, H., Poliwoda, H., and Deicher, H., 1987, Clinical significance of anti-IFN-antibody titers during interferon therapy, Lancet 2:635–636.

    Article  Google Scholar 

  • Von Wussow, P., Jakschies, D., Freund, M., and Deicher, H., 1989, Humoral response to recombinant interferon-α2b in patients receiving recombinant interferon-α2b therapy, J. Interferon Res. 9(Suppl. 1):S25–S31.

    Google Scholar 

  • Working, P. K., Golub, M. S., and Green, J. D., 1991, Maternal and neonatal safety of synthetic human relaxin administered to near-term pregnant rhesus monkeys, Toxicologist 11: 343.

    Google Scholar 

  • Wroblewska, Z., Gilden, D., Green, M., Devlin, M., and Vafai, A., 1985, Affinitypurified varicella-zoster glycoprotein gp1/gp3 stimulates the production of neutralising antibody, J. Gen. Virol. 66:1795–1799.

    Article  PubMed  CAS  Google Scholar 

  • Zoon, K. C., 1987, Human Interferons: Structure and Function, Academic Press, New York.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Toxicology, Liposome Technology, Inc., Menlo Park, California, 94025, USA

    Peter K. Working

Authors
  1. Peter K. Working
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. R. W. Johnson Pharmaceutical Research Institute, Spring House, Pennsylvania, USA

    Bobbe L. Ferraiolo

  2. Genentech, Inc., South San Francisco, California, USA

    Marjorie A. Mohler

  3. Alkermes, Inc., Cambridge, Massachusetts, USA

    Carol A. Gloff

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Working, P.K. (1992). Potential Effects of Antibody Induction by Protein Drugs. In: Ferraiolo, B.L., Mohler, M.A., Gloff, C.A. (eds) Protein Pharmacokinetics and Metabolism. Pharmaceutical Biotechnology, vol 1. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2329-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-2329-5_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-2331-8

  • Online ISBN: 978-1-4899-2329-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation